Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 28;4(1):39-46.
doi: 10.1002/ags3.12307. eCollection 2020 Jan.

Essential advances in surgical and adjuvant therapies for colorectal cancer 2018-2019

Tomonori Akagi  1 , Masafumi Inomata  1
Affiliations
Review

Essential advances in surgical and adjuvant therapies for colorectal cancer 2018-2019

Tomonori Akagi et al. Ann Gastroenterol Surg. .

Abstract

Surgical resection and adjuvant chemotherapy are the only treatment modalities for localized colorectal cancer that can obtain a "cure." The goal in surgically treating primary colorectal cancer is complete tumor removal along with dissection of systematic D3 lymph nodes. Adjuvant treatment controls recurrence and improves the prognosis of patients after they undergo R0 resection. Various clinical studies have promoted the gradual spread and clinical use of new surgical approaches such as laparoscopic surgery, robotic surgery, and transanal total mesorectal excision (TaTME). Additionally, the significance of adjuvant chemotherapy has been established and it is now recommended in the JSCCR (the Japanese Society for Cancer of the Colon and Rectum) guideline as a standard treatment. Herein, we review and summarize current surgical treatment and adjuvant chemotherapy for localized colorectal cancer and discuss recent advances in personalized medicine related to adjuvant chemotherapy.

Keywords: adjuvant chemotherapy; colorectal cancer; surgical treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Authors declare no conflict of interest for this article.

References

    1. Vital Statistics of Japan. [cited 2019 December]. Available from https://www.mhlw.go.jp/english/database/db-hw/vs01.html
    1. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. - PMC - PubMed
    1. Andre T, Boni C, Mounedji‐Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. - PubMed
    1. Haller DG, Tabernero J, Maroun J, de Braud F Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71. - PubMed
    1. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C‐08. J Clin Oncol. 2011;29(1):11–6. - PMC - PubMed